KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Pacira BioSciences (PCRX) over the last 10 years, with Jun 2025 value amounting to $16.9 million.

  • Pacira BioSciences' Gains from Investment Securities rose 99.30% to $16.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.9 million, marking a year-over-year decrease of 76.20%. This contributed to the annual value of -$4.5 million for FY2024, which is 30.17% down from last year.
  • According to the latest figures from Q2 2025, Pacira BioSciences' Gains from Investment Securities is $16.9 million, which was up 386.85% from -$5.9 million recorded in Q1 2025.
  • In the past 5 years, Pacira BioSciences' Gains from Investment Securities registered a high of $16.9 million during Q2 2025, and its lowest value of -$21.3 million during Q2 2022.
  • In the last 3 years, Pacira BioSciences' Gains from Investment Securities had a median value of $1.6 million in 2023 and averaged $311,900.
  • As far as peak fluctuations go, Pacira BioSciences' Gains from Investment Securities surged by 1,184.78% in 2023, and later crashed by 3,417.26% in 2024.
  • Pacira BioSciences' Gains from Investment Securities (Quarterly) stood at $404,000 in 2021, then crashed by 1,605.45% to -$6.1 million in 2022, then surged by 106.95% to $423,000 in 2023, then tumbled by 3,417.26% to -$14.0 million in 2024, then skyrocketed by 99.30% to $16.9 million in 2025.
  • Its Gains from Investment Securities stands at $16.9 million for Q2 2025, versus -$5.9 million for Q1 2025 and -$14.0 million for Q4 2024.